Last updated on August 2019

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Brief description of study

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

Clinical Study Identifier: NCT03980730

Find a site near you

Start Over

The Roskamp Institute

Sarasota, FL United States
  Connect »